Tokai Pharmaceuticals is focused on developing and delivering innovative therapies that provide hope and healing for patients living with cancer. Our lead product candidate is galeterone, a highly-selective, oral small molecule that is currently being developed for patients with metastatic, castration-resistant prostate cancer whose prostate tumor cells express the AR-V7 splice variant, which is a truncated form of the androgen receptor. We have global development and commercial rights to galeterone. Our pipeline also includes an ongoing program to identify and develop novel compounds designed to disrupt androgen receptor signaling through enhanced androgen receptor degradation.